Trial NCT04505722
Publication ENSEMBLE, *, 2021
Primary outcome on the report: The originally specified primary endpoint was efficacy of the vaccine to prevent centrally confirmed, moderate to severe/critical COVID-19 occurring at least 14 days post-vaccination in SARS-CoV-2 seronegative adults (with “seronegative” defined as negative RT-PCR and negative serology against SARS-CoV-2 nucleocapsid on Day 1).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.